ClearPoint Neuro, Inc. announced a strategic financing package with Oberland Capital Management LLC, providing access to up to $105 million in debt financing. An initial $30.0 million in gross proceeds was funded at closing, yielding $32.0 million in net proceeds.
The financing agreement includes two additional tranches: $25.0 million available at the company's option through December 31, 2026, and up to $50.0 million available at the option of both the company and Oberland Capital through the same date. This structure provides significant capital flexibility for future growth initiatives.
The terms of the Oberland notes include interest payments at Term SOFR + 3.95% (with a minimum of 8.25% and a cap of 9.5%), with 50% paid-in-kind for the first six quarters. The agreement also features a revenue participation clause, where 0.38% of Net Revenue up to $50 million per year will be paid starting January 1, 2027, increasing pro rata with additional tranches. The notes mature on the sixth anniversary of the closing date and are secured by substantially all company assets, including intellectual property.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.